-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $120

Benzinga·11/06/2026 19:16:05
Canaccord Genuity analyst Jason Mills maintains TransMedics Group (NASDAQ:TMDX) with a Buy and raises the price target from $95 to $120.